| Trial ID: | L0366 |
| Source ID: | NCT02279407
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
|
| Acronym: |
EFFECTII
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT02279407/results
|
| Conditions: |
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
|
| Interventions: |
Drug: placebo|Drug: Omega-3 carboxylic acids|Drug: Dapagliflozin|Drug: Placebo
|
| Outcome Measures: |
Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo)|Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups)
|
| Sponsor/Collaborators: |
AstraZeneca|Uppsala Clinical Research, Uppsala, Sweden
|
| Gender: |
All
|
| Age: |
40 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
223
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
January 2015
|
| Completion Date: |
December 2015
|
| Results First Posted: |
January 27, 2017
|
| Last Update Posted: |
March 17, 2017
|
| Locations: |
Research Site, G??teborg, Sweden|Research Site, Linkoping, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, ??rebro, Sweden
|
| URL: |
https://ClinicalTrials.gov/show/NCT02279407
|
